Register:
|
EUCTR |
Last refreshed on:
|
30 June 2019 |
Main ID: |
EUCTR2006-005513-35-CZ |
Date of registration:
|
19/02/2007 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Assess the LDL-C Lowering of Switching to a Combination tablet Ezetimibe/Simvastatin (10mg/20mg) compared to Rosuvastatin 10mg in patients with primary hypercholesterolemia and high cardiovascular risk and not adequately controlled with a prior statin treatment. (IN-CROSS). - Study to Assess the LDL-C Lowering of Switching to a Combination Tablet, Ezetimibe/Simvastatin (10mg
|
Scientific title:
|
A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Assess the LDL-C Lowering of Switching to a Combination tablet Ezetimibe/Simvastatin (10mg/20mg) compared to Rosuvastatin 10mg in patients with primary hypercholesterolemia and high cardiovascular risk and not adequately controlled with a prior statin treatment. (IN-CROSS). - Study to Assess the LDL-C Lowering of Switching to a Combination Tablet, Ezetimibe/Simvastatin (10mg |
Date of first enrolment:
|
19/02/2007 |
Target sample size:
|
56 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-005513-35 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes Randomised: yes Open: no Single blind: no Double blind: yes Parallel group: yes Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: yes Placebo: yes Other: yes Other specify the comparator: Rosuvastatin
|
Phase:
|
Human pharmacology (Phase I):
Therapeutic exploratory (Phase II):
Therapeutic confirmatory - (Phase III):
Therapeutic use (Phase IV): yes
|